Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept.
Nisotirostide showed a weight reduction of 0.75 kg versus placebo and 2.58 kg when added to dulaglutide, but the clinical significance of these findings remains uncertain.
Where it sits
this study against the rest of the dulaglutide corpusSummary and findings
Nisotirostide is a selective NPY2 receptor agonist evaluated for its effects on body weight and glucose control in type 2 diabetes. In a Phase 1 study involving 65 participants, a 1 mg dose of nisotirostide resulted in a 0.75 kg weight reduction versus placebo, while a combination with dulaglutide led to a 2.58 kg reduction. Adverse events were primarily gastrointestinal and dose-dependent.
Abstract
<h4>Background/objectives</h4>Nisotirostide is a novel selective NPY2 receptor agonist under development as adjunctive therapy for people with type 2 diabetes (T2D) on glucagon-like peptide-1 receptor agonists (GLP-1 RA).<h4>Methods</h4>Nisotirostide binding affinity and potency were determined against human NPY2 receptor. Effects of nisotirostide on body weight, food intake, body composition, glucose, and insulin were evaluated in mouse models. A Phase 1 study in healthy participants and participants with T2D on 1.5 mg once-weekly dose of dulaglutide evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics, following a single subcutaneous dose of nisotirostide ranging from 0.025 to 1 mg.<h4>Results</h4>Nisotirostide potently and selectively activated NPY2 receptor signaling in vitro. In mice, nisotirostide reduced body weight by up to 12% as monotherapy and up to 31% when combined with GLP-1 RA, demonstrating synergism. Nisotirostide-treated mice showed improved glucose control, independent of weight loss. In Phase 1 clinical study (N = 65), PK of nisotirostide supported a once-weekly dosing regimen. A 1 mg dose of nisotirostide in monotherapy reduced mean body weight by 0.75 kg versus placebo (ns); when added to dulaglutide, up to 2.58 kg reduction was observed versus dulaglutide alone (p < 0.05). Gastrointestinal adverse events, such as nausea and vomiting, were the most commonly reported with nisotirostide; these were dose-dependent and mild-to-moderate in severity.<h4>Conclusions</h4>Nisotirostide demonstrated potent, selective NPY2R agonism with a PK profile supporting once-weekly dosing. Preclinical metabolic benefits, including weight-independent glucose improvements, translated clinically, and a manageable tolerability profile supports further development as adjunctive GLP-1 RA therapy for T2D and obesity.<h4>Clinicaltrials</h4>gov number: NCT04641312.
Background
This paper addresses the development of nisotirostide as an adjunctive therapy for type 2 diabetes, particularly in patients already on GLP-1 receptor agonists. Prior research has established the role of NPY2 receptor agonists in metabolic regulation, but clinical evidence for nisotirostide's efficacy and safety is limited. This study is significant as it explores the potential of nisotirostide to enhance weight loss and glucose control in a clinical setting.
Methods
The study included a Phase 1 clinical trial with 65 participants, both healthy and those with type 2 diabetes, receiving a single subcutaneous dose of nisotirostide ranging from 0.025 to 1 mg. The primary outcomes included safety, tolerability, pharmacokinetics, and pharmacodynamics. Mouse models were also used to evaluate the effects on body weight, food intake, body composition, glucose, and insulin.
Results
The primary endpoint showed that a 1 mg dose of nisotirostide reduced mean body weight by 0.75 kg versus placebo (ns). In combination with dulaglutide, a reduction of up to 2.58 kg was observed compared to dulaglutide alone (p < 0.05). The study reported gastrointestinal adverse events, which were mild-to-moderate and dose-dependent.
Interpretation
While the findings indicate a statistically significant reduction in body weight when nisotirostide is combined with dulaglutide, the clinical significance of a 2.58 kg reduction may be limited in terms of long-term weight management. The study's small sample size and the absence of long-term follow-up data raise concerns about the robustness of the conclusions. The gastrointestinal side effects noted may also impact patient adherence to treatment.
Key findings
- Nisotirostide reduced body weight by up to 12% as monotherapy in mice.
- Nisotirostide reduced mean body weight by 0.75 kg versus placebo (ns) in Phase 1 study.
- When added to dulaglutide, up to 2.58 kg reduction was observed versus dulaglutide alone (p < 0.05).
- Gastrointestinal adverse events were dose-dependent and mild-to-moderate in severity.
Limitations
- small sample size (n=65)
- short duration of follow-up
- primarily assessed safety and pharmacokinetics
- no long-term efficacy data
- adverse events reported were mild-to-moderate